MoCD Type A is a rapidly progressive autosomal recessive inborn error of metabolism resulting in toxic sulfite levels causing neurologic sequelae
The hospital has taken a huge step by offering “Titli-palliative care services at home” to provide curative, restorative, and life-prolonging treatment to seriously ill children
Dr. Mona frequently treats children experiencing localized reactions from insect bites and stings.
If approved, Tafinlar + Mekinist may offer a potential new standard-of-care for pediatric patients with this brain cancer
Paxlovid is the first oral therapy specifically designed to combat Covid-19 to be evaluated in a pediatric clinical study
Dr. Peter Houghton will lead the research collaboration for GCCRI and is widely regarded as a leading expert in pediatric cancer research and in the development of novel approaches to treating childhood cancers
Cosentyx is a proven treatment, supported by long-term five-year sustained efficacy and safety data across several inflammatory conditions and with more than 500,000 patients treated worldwide since launch
The approval is grounded in data from a Phase III randomized, double-blind, placebo-controlled, crossover study in NPC patients
This innovation enhances viral stability, preserves potency, and reduces allergic reactions and antigen crystallisation-related issues
The findings, from the SPACE study, paved the way for FDA approval of AJOVY for pediatric patients aged 6-17 years weighing 45 kilograms
Subscribe To Our Newsletter & Stay Updated
